Union plans Phase III trial for atopic dermatitis after Phase IIb win

By Yahoo! Finance | Sep 26, 2024 at 10:42 AM EST

Union Therapeutics is moving forward with its PDE4 inhibitor, orismilast, to a Phase III clinical trial for atopic dermatitis after positive Phase IIb study results. The company is exploring its potential for various inflammatory conditions.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.